Skip to content
  • Media
  • Investors
  • Media
  • Investors
  • TAMP Therapy Platform
    • Our Science
    • RenovoCath®
  • Physicians
    • Evidence
    • Resources
  • Patients
    • The Procedure
    • FAQs
    • Patient Stories
    • Physician Locator
  • About Us
    • Overview & Leadership
    • Board of Directors
    • Advisory Boards
  • Contact
  • Media
  • Investors
  • TAMP Therapy Platform
    • Our Science
    • RenovoCath®
  • Physicians
    • Evidence
    • Resources
  • Patients
    • The Procedure
    • FAQs
    • Patient Stories
    • Physician Locator
  • About Us
    • Overview & Leadership
    • Board of Directors
    • Advisory Boards
  • Contact
  • Media
  • Investors

Day: February 5, 2026

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

RenovoRx is pleased to announce the appointment of Mark Voll as the Company’s Chief Financial Officer, effective February 1, 2026.

RenovoCath is FDA-cleared for targeted delivery of chemotherapy to selected sites in the peripheral vascular system. The company is studying the use of RenovoCath-delivered gemcitabine for treatment of LAPC in an ongoing clinical trial conducted under an IND.

Facebook-f X-twitter Linkedin-in Youtube

Menu

  • TAMP Therapy Platform
  • Our Science
  • RenovoCath®
  • Physicians
  • Evidence
  • Clinical Trials
  • Patients
  • The Procedure
  • FAQs
  • Patient Stories
  • Physician Locator
  • About
  • Leadership
  • Board of Directors
  • Advisory Boards
  • Contact
  • TAMP Therapy Platform
  • Our Science
  • RenovoCath®
  • Physicians
  • Evidence
  • Clinical Trials
  • Patients
  • The Procedure
  • FAQs
  • Patient Stories
  • Physician Locator
  • About
  • Leadership
  • Board of Directors
  • Advisory Boards
  • Contact
  • 2570 W. El Camino Real, Suite 640
    Mountain View, CA 94040
  • (650) 284-4433
  • info@renovorx.com
© 2026 RenovoRx®. All rights reserved.

Privacy Statement | Terms of Use